A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Immunovant, Inc. IMVT
Weak (early) broader-coverage candidate · Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune c
On FrontierLab's discovery record since 2026-09-10 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-11), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | 0.01 |
| Rule of 40 | — |
| Net margin | -7877.5% |
| Cash runway (months) | 23.1 |
| PEG | — |
| Price / sales | 1108.4 |
Quality checklist
- ✗ Capital efficiency
- ✓ Share dilution — 20.3%
Fundamentals — snapshot as of 2026-09-11
| Stage | Early |
|---|---|
| Share issuance (YoY) | 20.3% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-2.82 |
| Burn multiple | 58.4 |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.94 |
| Net debt / EBITDA | — |
| Statements as of | Q1 FY2027 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-09-11, not current
| Price at surface | $38.10 (as of 2026-09-11) |
|---|---|
| 52-week range | $14.58 – $45.42 |
| % off 52-wk high | -16.1% |
| RSI (14) | 35 |
| Relative volume | 0.9× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-11 (end-of-day). How grades are computed →